Karo Bio: Presentation of the Interim Report

Regulatory News:

Karo Bio (STO:KARO) publishes its interim report for the period January – September 2011 on October 25, 2011 at 8.30 am CET. On the same day, at 10:00 CET, acting President, Per Bengtsson, presents the report in an audiocast. The presentation will be held in Swedish and can be followed by audiocast on the following link:

http://financialhearings.nu/111025/karobio/ (http://financialhearings.nu/111025/karobio/)

Please use the following numbers to participate by telephone:

+46 (0) 8 505 598 09
+44 (0) 20 710 863 03

About Karo Bio

Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas cardiovascular and metabolic diseases, neuropsychiatry, inflammation, autoimmune diseases, cancer and women’s health. An important foundation for the company’s activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 70 employees and is listed on NASDAQ OMX Stockholm.

This press release is also available online at www.karobio.se and www.newsroom.cision.com (http://www.newsroom.cision.com)

This information was brought to you by Cision http://www.cisionwire.com